Related Experiment Videos
New anticancer agents in clinical development
J Eckardt1, G Eckhardt, M Villalona-Calero
1Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, USA.
Abstract:
A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; and the paclitaxel analog docetaxel. The authors discussed these new agents last month. In Part 2 of their article, they describe gemcitabine, an antimetabolite structurally related to cytarabine; fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors, and new approaches to anticancer therapy, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.
Insights
New anticancer drugs targeting cancer cell biology are in clinical trials. These include topoisomerase I inhibitors, docetaxel, gemcitabine, thymidylate synthase inhibitors, and novel therapies like angiogenesis inhibitors and gene therapy.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Advances in cancer cell biology and biochemistry drive the development of novel antineoplastic agents.
- Existing and emerging cancer therapies are crucial for improving patient outcomes.
Purpose of the Study:
- To review promising new antineoplastic compounds currently in clinical trials.
- To discuss novel therapeutic strategies beyond traditional chemotherapy.
Main Methods:
- Review of current literature on anticancer drug development.
- Categorization of new agents based on their mechanism of action.
Main Results:
- Several classes of new antineoplastic drugs are progressing through clinical trials.
- Notable examples include topoisomerase I inhibitors (e.g., irinotecan, topotecan) and paclitaxel analogs (e.g., docetaxel).
- Other agents discussed include gemcitabine, thymidylate synthase inhibitors, angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.
Conclusions:
- The pipeline for cancer therapeutics is robust, with diverse mechanisms of action.
- These novel agents represent significant advancements in the fight against cancer.